Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
AbbVie Inc., solvency ratios (quarterly data)
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | AbbVie Inc. debt to equity ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | AbbVie Inc. debt to capital ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | AbbVie Inc. debt to assets ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | AbbVie Inc. financial leverage ratio increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Debt to Equity
AbbVie Inc., debt to equity calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Short-term borrowings | —) | 2) | —) | 1) | 1) | 10) | 17) | 12) | 14) | 16) | 17) | 9) | 34) | 54) | 64) | 6) | —) | —) | 306) | 499) | ||||||
| Current portion of long-term debt and finance lease obligations | 7,191) | 5,113) | 5,203) | 2,800) | 4,135) | 9,197) | 11,913) | 9,940) | 12,481) | 6,656) | 7,884) | 11,338) | 8,468) | 4,723) | 5,307) | 3,756) | 3,753) | 5,276) | 5,335) | 1,579) | ||||||
| Long-term debt and finance lease obligations, excluding current portion | 52,194) | 55,631) | 55,812) | 59,292) | 59,135) | 60,399) | 61,002) | 63,522) | 64,189) | 74,049) | 74,237) | 74,183) | 77,554) | 82,282) | 82,061) | 63,284) | 62,975) | 33,126) | 31,619) | 35,066) | ||||||
| Total debt | 59,385) | 60,746) | 61,015) | 62,093) | 63,271) | 69,606) | 72,932) | 73,474) | 76,684) | 80,721) | 82,138) | 85,530) | 86,056) | 87,059) | 87,432) | 67,046) | 66,728) | 38,402) | 37,260) | 37,144) | ||||||
| Stockholders’ equity (deficit) | 10,360) | 12,094) | 12,866) | 13,274) | 17,254) | 15,994) | 14,653) | 16,283) | 15,408) | 13,550) | 12,569) | 13,710) | 13,076) | 15,270) | 14,708) | (7,415) | (8,172) | (8,226) | (8,566) | (7,826) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to equity1 | 5.73 | 5.02 | 4.74 | 4.68 | 3.67 | 4.35 | 4.98 | 4.51 | 4.98 | 5.96 | 6.53 | 6.24 | 6.58 | 5.70 | 5.94 | — | — | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||
| Amgen Inc. | 10.37 | 7.90 | 9.08 | 11.52 | 10.64 | 10.60 | 15.10 | 40.23 | 4.97 | 4.57 | 3.98 | 3.50 | 3.51 | 3.13 | 3.21 | 3.36 | 3.09 | 2.73 | 2.84 | 3.05 | ||||||
| Bristol-Myers Squibb Co. | 1.35 | 1.30 | 1.18 | 1.19 | 1.27 | 1.20 | 1.29 | 1.42 | 1.24 | 1.20 | 1.23 | 1.23 | 1.34 | 0.90 | 0.95 | 0.94 | 0.91 | 1.41 | 1.56 | 0.40 | ||||||
| Eli Lilly & Co. | 2.34 | 1.80 | 1.70 | 1.69 | 1.52 | 1.58 | 1.97 | 1.77 | 1.88 | 2.20 | 2.56 | 2.35 | 2.94 | 3.51 | 3.99 | 5.60 | 5.88 | 4.50 | 5.68 | 6.44 | ||||||
| Gilead Sciences Inc. | 1.09 | 1.12 | 1.19 | 1.20 | 1.19 | 1.20 | 1.30 | 1.32 | 1.27 | 1.29 | 1.53 | 1.59 | 1.73 | 1.68 | 1.34 | 1.09 | 1.09 | 1.19 | 1.15 | 1.21 | ||||||
| Johnson & Johnson | 0.43 | 0.42 | 0.61 | 0.75 | 0.52 | 0.43 | 0.43 | 0.44 | 0.46 | 0.48 | 0.48 | 0.51 | 0.56 | 0.59 | 0.48 | 0.45 | 0.47 | 0.50 | 0.48 | 0.50 | ||||||
| Merck & Co. Inc. | 0.93 | 0.85 | 0.95 | 0.66 | 0.67 | 0.68 | 0.73 | 0.78 | 0.87 | 0.74 | 0.80 | 1.16 | 1.26 | 0.98 | 1.12 | 1.07 | 1.02 | 0.97 | 0.96 | 0.94 | ||||||
| Pfizer Inc. | 0.81 | 0.66 | 0.66 | 0.36 | 0.37 | 0.40 | 0.46 | 0.44 | 0.50 | 0.53 | 0.56 | 0.58 | 0.63 | 0.97 | 0.99 | 0.80 | 0.83 | 0.81 | 0.78 | 0.77 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.10 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.14 | 0.16 | 0.18 | 0.23 | 0.24 | 0.27 | 0.24 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | ||||||
| Thermo Fisher Scientific Inc. | 0.75 | 0.78 | 0.78 | 0.83 | 0.78 | 0.67 | 0.72 | 0.81 | 0.85 | 0.56 | 0.51 | 0.53 | 0.63 | 0.66 | 0.71 | 0.70 | 0.60 | 0.58 | 0.66 | 0.66 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= 59,385 ÷ 10,360 = 5.73
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | AbbVie Inc. debt to equity ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Debt to Capital
AbbVie Inc., debt to capital calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Short-term borrowings | —) | 2) | —) | 1) | 1) | 10) | 17) | 12) | 14) | 16) | 17) | 9) | 34) | 54) | 64) | 6) | —) | —) | 306) | 499) | ||||||
| Current portion of long-term debt and finance lease obligations | 7,191) | 5,113) | 5,203) | 2,800) | 4,135) | 9,197) | 11,913) | 9,940) | 12,481) | 6,656) | 7,884) | 11,338) | 8,468) | 4,723) | 5,307) | 3,756) | 3,753) | 5,276) | 5,335) | 1,579) | ||||||
| Long-term debt and finance lease obligations, excluding current portion | 52,194) | 55,631) | 55,812) | 59,292) | 59,135) | 60,399) | 61,002) | 63,522) | 64,189) | 74,049) | 74,237) | 74,183) | 77,554) | 82,282) | 82,061) | 63,284) | 62,975) | 33,126) | 31,619) | 35,066) | ||||||
| Total debt | 59,385) | 60,746) | 61,015) | 62,093) | 63,271) | 69,606) | 72,932) | 73,474) | 76,684) | 80,721) | 82,138) | 85,530) | 86,056) | 87,059) | 87,432) | 67,046) | 66,728) | 38,402) | 37,260) | 37,144) | ||||||
| Stockholders’ equity (deficit) | 10,360) | 12,094) | 12,866) | 13,274) | 17,254) | 15,994) | 14,653) | 16,283) | 15,408) | 13,550) | 12,569) | 13,710) | 13,076) | 15,270) | 14,708) | (7,415) | (8,172) | (8,226) | (8,566) | (7,826) | ||||||
| Total capital | 69,745) | 72,840) | 73,881) | 75,367) | 80,525) | 85,600) | 87,585) | 89,757) | 92,092) | 94,271) | 94,707) | 99,240) | 99,132) | 102,329) | 102,140) | 59,631) | 58,556) | 30,176) | 28,694) | 29,318) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to capital1 | 0.85 | 0.83 | 0.83 | 0.82 | 0.79 | 0.81 | 0.83 | 0.82 | 0.83 | 0.86 | 0.87 | 0.86 | 0.87 | 0.85 | 0.86 | 1.12 | 1.14 | 1.27 | 1.30 | 1.27 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||
| Amgen Inc. | 0.91 | 0.89 | 0.90 | 0.92 | 0.91 | 0.91 | 0.94 | 0.98 | 0.83 | 0.82 | 0.80 | 0.78 | 0.78 | 0.76 | 0.76 | 0.77 | 0.76 | 0.73 | 0.74 | 0.75 | ||||||
| Bristol-Myers Squibb Co. | 0.57 | 0.56 | 0.54 | 0.54 | 0.56 | 0.54 | 0.56 | 0.59 | 0.55 | 0.55 | 0.55 | 0.55 | 0.57 | 0.47 | 0.49 | 0.48 | 0.48 | 0.59 | 0.61 | 0.28 | ||||||
| Eli Lilly & Co. | 0.70 | 0.64 | 0.63 | 0.63 | 0.60 | 0.61 | 0.66 | 0.64 | 0.65 | 0.69 | 0.72 | 0.70 | 0.75 | 0.78 | 0.80 | 0.85 | 0.85 | 0.82 | 0.85 | 0.87 | ||||||
| Gilead Sciences Inc. | 0.52 | 0.53 | 0.54 | 0.55 | 0.54 | 0.54 | 0.56 | 0.57 | 0.56 | 0.56 | 0.60 | 0.61 | 0.63 | 0.63 | 0.57 | 0.52 | 0.52 | 0.54 | 0.54 | 0.55 | ||||||
| Johnson & Johnson | 0.30 | 0.30 | 0.38 | 0.43 | 0.34 | 0.30 | 0.30 | 0.31 | 0.31 | 0.33 | 0.32 | 0.34 | 0.36 | 0.37 | 0.33 | 0.31 | 0.32 | 0.33 | 0.33 | 0.33 | ||||||
| Merck & Co. Inc. | 0.48 | 0.46 | 0.49 | 0.40 | 0.40 | 0.41 | 0.42 | 0.44 | 0.46 | 0.42 | 0.44 | 0.54 | 0.56 | 0.50 | 0.53 | 0.52 | 0.50 | 0.49 | 0.49 | 0.48 | ||||||
| Pfizer Inc. | 0.45 | 0.40 | 0.40 | 0.26 | 0.27 | 0.28 | 0.32 | 0.31 | 0.33 | 0.35 | 0.36 | 0.37 | 0.39 | 0.49 | 0.50 | 0.45 | 0.45 | 0.45 | 0.44 | 0.43 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.14 | 0.15 | 0.18 | 0.20 | 0.21 | 0.20 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | ||||||
| Thermo Fisher Scientific Inc. | 0.43 | 0.44 | 0.44 | 0.45 | 0.44 | 0.40 | 0.42 | 0.45 | 0.46 | 0.36 | 0.34 | 0.35 | 0.39 | 0.40 | 0.42 | 0.41 | 0.37 | 0.37 | 0.40 | 0.40 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= 59,385 ÷ 69,745 = 0.85
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | AbbVie Inc. debt to capital ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Debt to Assets
AbbVie Inc., debt to assets calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Short-term borrowings | —) | 2) | —) | 1) | 1) | 10) | 17) | 12) | 14) | 16) | 17) | 9) | 34) | 54) | 64) | 6) | —) | —) | 306) | 499) | ||||||
| Current portion of long-term debt and finance lease obligations | 7,191) | 5,113) | 5,203) | 2,800) | 4,135) | 9,197) | 11,913) | 9,940) | 12,481) | 6,656) | 7,884) | 11,338) | 8,468) | 4,723) | 5,307) | 3,756) | 3,753) | 5,276) | 5,335) | 1,579) | ||||||
| Long-term debt and finance lease obligations, excluding current portion | 52,194) | 55,631) | 55,812) | 59,292) | 59,135) | 60,399) | 61,002) | 63,522) | 64,189) | 74,049) | 74,237) | 74,183) | 77,554) | 82,282) | 82,061) | 63,284) | 62,975) | 33,126) | 31,619) | 35,066) | ||||||
| Total debt | 59,385) | 60,746) | 61,015) | 62,093) | 63,271) | 69,606) | 72,932) | 73,474) | 76,684) | 80,721) | 82,138) | 85,530) | 86,056) | 87,059) | 87,432) | 67,046) | 66,728) | 38,402) | 37,260) | 37,144) | ||||||
| Total assets | 134,711) | 136,221) | 135,367) | 134,544) | 138,805) | 141,325) | 143,186) | 143,211) | 146,529) | 148,858) | 147,972) | 150,501) | 150,565) | 149,621) | 149,530) | 91,199) | 89,115) | 59,441) | 57,142) | 56,769) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to assets1 | 0.44 | 0.45 | 0.45 | 0.46 | 0.46 | 0.49 | 0.51 | 0.51 | 0.52 | 0.54 | 0.56 | 0.57 | 0.57 | 0.58 | 0.58 | 0.74 | 0.75 | 0.65 | 0.65 | 0.65 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||
| Amgen Inc. | 0.67 | 0.67 | 0.68 | 0.69 | 0.60 | 0.61 | 0.62 | 0.62 | 0.54 | 0.58 | 0.55 | 0.52 | 0.52 | 0.53 | 0.53 | 0.52 | 0.50 | 0.50 | 0.52 | 0.52 | ||||||
| Bristol-Myers Squibb Co. | 0.42 | 0.41 | 0.40 | 0.40 | 0.41 | 0.40 | 0.42 | 0.44 | 0.41 | 0.40 | 0.41 | 0.41 | 0.43 | 0.36 | 0.36 | 0.36 | 0.36 | 0.43 | 0.45 | 0.17 | ||||||
| Eli Lilly & Co. | 0.39 | 0.35 | 0.34 | 0.36 | 0.33 | 0.33 | 0.36 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.36 | 0.39 | 0.39 | 0.42 | 0.39 | 0.40 | 0.41 | 0.42 | ||||||
| Gilead Sciences Inc. | 0.40 | 0.40 | 0.40 | 0.41 | 0.40 | 0.40 | 0.42 | 0.42 | 0.39 | 0.41 | 0.44 | 0.45 | 0.46 | 0.48 | 0.43 | 0.40 | 0.40 | 0.42 | 0.41 | 0.42 | ||||||
| Johnson & Johnson | 0.18 | 0.18 | 0.24 | 0.27 | 0.21 | 0.18 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.20 | 0.22 | 0.19 | 0.18 | 0.18 | 0.19 | 0.19 | 0.20 | ||||||
| Merck & Co. Inc. | 0.33 | 0.33 | 0.35 | 0.29 | 0.28 | 0.28 | 0.30 | 0.30 | 0.31 | 0.28 | 0.29 | 0.34 | 0.35 | 0.32 | 0.34 | 0.33 | 0.31 | 0.31 | 0.32 | 0.31 | ||||||
| Pfizer Inc. | 0.32 | 0.30 | 0.30 | 0.18 | 0.18 | 0.19 | 0.21 | 0.20 | 0.21 | 0.22 | 0.23 | 0.25 | 0.26 | 0.35 | 0.36 | 0.31 | 0.31 | 0.31 | 0.30 | 0.29 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.13 | 0.15 | 0.16 | 0.17 | 0.15 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | ||||||
| Thermo Fisher Scientific Inc. | 0.35 | 0.36 | 0.36 | 0.37 | 0.35 | 0.32 | 0.33 | 0.36 | 0.37 | 0.29 | 0.28 | 0.28 | 0.31 | 0.33 | 0.35 | 0.34 | 0.30 | 0.30 | 0.33 | 0.33 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= 59,385 ÷ 134,711 = 0.44
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | AbbVie Inc. debt to assets ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Financial Leverage
AbbVie Inc., financial leverage calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Total assets | 134,711) | 136,221) | 135,367) | 134,544) | 138,805) | 141,325) | 143,186) | 143,211) | 146,529) | 148,858) | 147,972) | 150,501) | 150,565) | 149,621) | 149,530) | 91,199) | 89,115) | 59,441) | 57,142) | 56,769) | ||||||
| Stockholders’ equity (deficit) | 10,360) | 12,094) | 12,866) | 13,274) | 17,254) | 15,994) | 14,653) | 16,283) | 15,408) | 13,550) | 12,569) | 13,710) | 13,076) | 15,270) | 14,708) | (7,415) | (8,172) | (8,226) | (8,566) | (7,826) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Financial leverage1 | 13.00 | 11.26 | 10.52 | 10.14 | 8.04 | 8.84 | 9.77 | 8.80 | 9.51 | 10.99 | 11.77 | 10.98 | 11.51 | 9.80 | 10.17 | — | — | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||
| Amgen Inc. | 15.59 | 11.83 | 13.31 | 16.59 | 17.79 | 17.44 | 24.51 | 64.62 | 9.13 | 7.91 | 7.25 | 6.70 | 6.69 | 5.90 | 6.10 | 6.50 | 6.17 | 5.45 | 5.50 | 5.91 | ||||||
| Bristol-Myers Squibb Co. | 3.23 | 3.15 | 2.92 | 2.96 | 3.12 | 3.01 | 3.08 | 3.26 | 3.04 | 2.98 | 3.01 | 2.99 | 3.13 | 2.50 | 2.61 | 2.59 | 2.52 | 3.25 | 3.44 | 2.29 | ||||||
| Eli Lilly & Co. | 5.94 | 5.16 | 4.95 | 4.75 | 4.65 | 4.71 | 5.51 | 5.03 | 5.44 | 6.21 | 7.42 | 6.79 | 8.27 | 9.10 | 10.25 | 13.35 | 15.07 | 11.20 | 13.91 | 15.32 | ||||||
| Gilead Sciences Inc. | 2.72 | 2.80 | 2.95 | 2.95 | 2.97 | 2.97 | 3.11 | 3.17 | 3.23 | 3.13 | 3.45 | 3.56 | 3.76 | 3.49 | 3.10 | 2.71 | 2.74 | 2.87 | 2.79 | 2.86 | ||||||
| Johnson & Johnson | 2.44 | 2.33 | 2.55 | 2.77 | 2.44 | 2.35 | 2.33 | 2.39 | 2.46 | 2.55 | 2.54 | 2.62 | 2.76 | 2.65 | 2.51 | 2.53 | 2.65 | 2.67 | 2.55 | 2.54 | ||||||
| Merck & Co. Inc. | 2.84 | 2.59 | 2.70 | 2.30 | 2.37 | 2.41 | 2.48 | 2.61 | 2.77 | 2.61 | 2.72 | 3.37 | 3.62 | 3.08 | 3.28 | 3.24 | 3.26 | 3.10 | 3.04 | 2.99 | ||||||
| Pfizer Inc. | 2.54 | 2.22 | 2.22 | 1.94 | 2.06 | 2.10 | 2.24 | 2.23 | 2.35 | 2.37 | 2.43 | 2.31 | 2.44 | 2.74 | 2.77 | 2.56 | 2.65 | 2.62 | 2.62 | 2.64 | ||||||
| Regeneron Pharmaceuticals Inc. | 1.27 | 1.29 | 1.28 | 1.28 | 1.29 | 1.29 | 1.32 | 1.32 | 1.36 | 1.37 | 1.42 | 1.48 | 1.56 | 1.59 | 1.59 | 1.30 | 1.34 | 1.33 | 1.35 | 1.36 | ||||||
| Thermo Fisher Scientific Inc. | 2.11 | 2.14 | 2.15 | 2.24 | 2.21 | 2.08 | 2.14 | 2.26 | 2.33 | 1.90 | 1.84 | 1.88 | 2.00 | 2.01 | 2.06 | 2.05 | 1.97 | 1.93 | 2.02 | 2.01 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= 134,711 ÷ 10,360 = 13.00
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | AbbVie Inc. financial leverage ratio increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |